Glycomine Incis A Clinical Stage Biotechnology Company Dedicated To Developing Disease Modifying Therapies For Serious Rare Genetic Disordersparticularly Those Related To Glycosylation And Protein Metabolismthe Company Focuses On Addressing Unmet Medical Needs In Rare Diseaseswhere Existing Treatments Primarily Manage Symptoms Rather Than Targeting The Underlying Causes One Of Glycomine S Key Products Is Glm101A Mannose 1 Phosphate Replacement Therapy Currently In Clinical Development For Pmm2 Cdgthe Most Common Congenital Disorder Of Glycosylationthe Company Is Committed To Improving The Quality Of Life For Patients With Ultra Rare Genetic Conditionsemphasizing The Importance Of Translational Science To Create Effective Therapiesglycomine Has Received Fda Fast Track Designation For Glm101Which Accelerates Its Developmentand Has Successfully Raised $115 Million In Funding To Support Its Clinical Trials And Expand Its Pipeline
China
